Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.
BACKGROUND
Ankylosing spondylitis (AS) is a chronic rheumatic disease associated with spinal inflammation that subsequently leads to progression of structural damage and loss of function. The fully human anti-tumor necrosis factor (anti-TNF) antibody adalimumab reduces the signs and symptoms and improves overall quality of life in patients with active AS; these benefits have been maintained through 2 years of treatment. Our objective was to compare the progression of structural damage in the spine in patients with AS treated with adalimumab for up to 2 years versus patients who had not received TNF antagonist therapy.


METHODS
Radiographs from patients with AS who received adalimumab 40 mg every other week subcutaneously were pooled from the Adalimumab Trial Evaluating Long-Term Efficacy and Safety for Ankylosing Spondylitis (ATLAS) study and a Canadian AS study (M03-606). Radiographic progression from baseline to 2 years in the spine of adalimumab-treated patients from these two studies (adalimumab cohort, n = 307) was compared with an historic anti-TNF-naïve cohort (Outcome in AS International Study [OASIS], n = 169) using the modified Stoke AS Spine Score (mSASSS) method.


RESULTS
mSASSS results were not significantly different between the adalimumab cohort and the OASIS cohort, based on baseline and 2-year radiographs. Mean changes in mSASSS from baseline to 2 years were 0.9 for the OASIS cohort and 0.8 for the adalimumab cohort (P = 0.771), indicating similar radiographic progression in both groups. When results for patients in the OASIS cohort who met the baseline disease activity criteria for the ATLAS and Canadian studies (OASIS-Eligible cohort) were analyzed, there was no significant difference in mean change in mSASSS from baseline to 2 years between OASIS-Eligible patients and adalimumab-treated patients; the mean changes in mSASSS were 0.9 for the OASIS-Eligible cohort and 0.8 for the adalimumab cohort (P = 0.744).


CONCLUSIONS
Two years of treatment with adalimumab did not slow radiographic progression in patients with AS, as assessed by the mSASSS scoring system, when compared with radiographic data from patients naïve to TNF antagonist therapy.
van der Heijde
Désirée
D
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. d.vanderheijde@kpnplanet.nl
Salonen
David
D
Weissman
Barbara N
BN
Landewé
Robert
R
Maksymowych
Walter P
WP
Kupper
Hartmut
H
Ballal
Shaila
S
Gibson
Eric
E
Wong
Robert
R
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D011859:Radiography; D016032:Randomized Controlled Trials as Topic; D013131:Spine / Q000000981:diagnostic imaging* / Q000187:drug effects; D013167:Spondylitis, Ankylosing / Q000000981:diagnostic imaging* / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab
Arthritis Rheum. 2006 Jul;54(7):2136-46
16802350
Ann Rheum Dis. 2005 Jul;64(7):981-7
15640265
J Clin Invest. 2002 Nov;110(10):1419-27
12438440
Arthritis Rheum. 2007 Feb;56(2):489-97
17265484
Ann Rheum Dis. 2009 Jun;68(6):922-9
18701556
Arthritis Rheum. 2008 Oct;58(10):3063-70
18821688
Arthritis Rheum. 2008 Mar;58(3):649-56
18311819
Arthritis Rheum. 2004 Aug;50(8):2622-32
15334477
Arthritis Rheum. 2004 Jul;50(7):2264-72
15248226
J Clin Invest. 2003 Mar;111(6):821-31
12639988
Ann Rheum Dis. 2006 Aug;65(8):1038-43
16439444
Arthritis Rheum. 2004 May;50(5):1400-11
15146409
Arthritis Rheum. 2005 Jun;52(6):1756-65
15934081
J Rheumatol. 2008 Oct;35(10):2030-7
18785308
Arthritis Rheum. 2005 Jul;52(7):1979-85
15986341
Arthritis Rheum. 2009 Jan;60(1):93-102
19116919
J Rheumatol. 2005 Oct;32(10):2048-9
16206368
Ann Rheum Dis. 2005 Jul;64(7):988-94
15958757
Arthritis Rheum. 1995 Apr;38(4):499-505
7718003
Arthritis Rheum. 2006 Apr;54(4):1063-74
16572441
Arthritis Res Ther. 2009;11(1):101
19183433
Arthritis Rheum. 1984 Apr;27(4):361-8
6231933
Arthritis Rheum. 2007 Jun;56(6):1846-53
17530713
Arthritis Rheum. 1998 Jan;41(1):58-67
9433870
J Clin Invest. 2000 Dec;106(12):1481-8
11120755
Arthritis Res Ther. 2008;10(5):R104
18761747
Rheumatology (Oxford). 2007 Sep;46(9):1450-3
17623745
Arthritis Rheum. 2008 May;58(5):1324-31
18438853
Arthritis Rheum. 2006 Jun;54(6):1736-46
16729286
Ann Rheum Dis. 2005 Jan;64(1):127-9
15051621